Date Added: 14/09/2017

Date Updated: 14/09/2017

Allogeneic mesenchymal stem cell and autologous T-cell therapies for the treatment of refractory Crohn’s disease

Specialties: Gastrointestinal, pancreatic and liver disease - Haematology & blood products

Technology Type: Procedures

Stage of development: Other

Stage of EAA: Assessment Complete

Description, patients and keywords:

Allogeneic mesenchymal stem cell and T-cell therapies to treat refractory Crohn’s disease are still in a developmental phase, with no indication to suggest any influence on clinical practice in Australia and New Zealand. Most evidence on the technologies is limited to case series.

Therapies such as stem cell treatment should be considered investigational and would only be applicable to a small proportion of patients with refractory Crohn’s disease who had failed conventional treatments.


This report is work in progress and should not be used for external distribution without permission from the originating agency. Users should be aware that reports are based on information available at the time of research and often on a limited literature search.